A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Markets
A pharma giant is moving past one patent cliff — but another is already looming
Private Trade News venue-risk note (2026-10-30): Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks. Primary source: original at CNBC Top News (cnbc.com).
Read also
Markets
Intel stock plunges 21% as chipmaker blames PC slowdown for weak guidance
Markets
ServiceNow shares plunge 25% after earnings revive AI disruption fears
Markets
Norwegian shares surge 13% on earnings beat, guidance raise
Markets